Analysis of patient characteristics and safety of insulin glargine U300 use in 21 359 patients with type‐2 diabetes and chronic kidney disease: DPV registry study

Documenti analoghi

• Effectiveness of add‐on therapy with SGLT2 inhibitors or GLP ‐1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study
  di: Christina Baechle, et al.
  Pubblicazione: (2024)
• Real‐life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use
  di: Jochen Seufert, et al.
  Pubblicazione: (2024)
• Efficacy and safety of insulin glargine 300 U/ mL in people with type 2 diabetes in China: The INITIATION study
  di: Liming Chen, et al.
  Pubblicazione: (2024)
• Insulin glargine 300 U/ mL safety data in pregnancy
  di: Jukka Westerbacka, et al.
  Pubblicazione: (2025)
• Effectiveness and safety of insulin glargine 300 U/mL in insulin‐naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis
  di: Pierre Gourdy, et al.
  Pubblicazione: (2024)